Nucleosyn
  • Home
  • Products
    • All products
    • Products categories
    • DNA-RNA
    • Synthetic lipids
    • Stable isotope
    • Custom chemical synthesis
  • Capabilities
  • About Us
  • Contact
  • Linkedin

My selection

Synthetic lipids

NucleoSyn produces and supplies synthetic lipids from milligrams to multi-kilos quantities.

ALC-0315

CAS #
2036272-55-4
Packing size
100 mg, 500 mg, 1 g, bulk (gram scale)
mRNA deliveryNanoparticleLNPLiposomeTransfectionCationic lipid
ALC-0315 Image 1

ALC-0315 is one of the components in the BNT162b2 (Pfizer-Biontech) vaccine against SARS-CoV-2. Administration of (SARS-CoV-2) mRNA in LNPs constructed from ALC-0315 induces the production of IgG that binds to the SARS-CoV-2 receptor-binding domain (RBD) in rhesus macaques.

Aspect
Colorless oil
Purity
98%
Solubility
DMSO, EtOH
Molecular weight
766,29
Molecular formula

C48H95NO5

IUPAC
((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate)

A. B. Vogel et al., Nature, 2021, 592, 7853, 283-289. read article

L. Schoenmaker et al., International Journal of Pharmaceutics, 2021, 601, 120586. read article

S. M. Moghimi, Mol. Ther., 2021, 29, 3, 898-900. read article

Purchase ALC-0315

Get a quote on this product

We're ready to solve any rare chemicals sourcing or molecular design problem... Give us a shout! Please fill out this form completely.

If you don't find a product in our current offer, please don't hesitate to request a quote using our contact form.

Add to my selection

Related products

[13C6]-Glucosylsphingosine ([13C6]-GlSph...
CAS #
299172-48-8
Details
[D5]-Phosphatidylethanol / [d5] - PEth a...
CAS #
1612140-92-7
Details
Glucosylsphingosine / (GlSph)
CAS #
52050-17-6
Details
See more products

logo footerNucleosyn

111 Bd Duhamel du Monceau

45160 Olivet

Products

See Catalog

Know more about products

Contact

Contact Form

+33 2 38 49 45 73

Follow us

Other Infos

Legal notices

Privacy Policy & cookies infos

General terms & conditions

© Nucleosyn 2025 - All rights reserved

Design and development Think Ad Communication